Updates From CROI 2019: Treatment of HIV and Its Complications

Slides:

Advertisements

Similar presentations

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

Advertisements

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Jointly Sponsored by: and Clinical Context: HIV/AIDS in Practice Expert Commentary.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

11 HIV and contraception – complex issues for safe choice: the latest recommendations from the World Health Organization (WHO) Mary Lyn Gaffield, Sharon.

Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.

ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.

Reproductive Health of People Living with HIV of People Living with HIV in Poland in Poland Tomasz Niemiec Other STD’s Neoplasmas Family Planning Demography.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Emerging comorbidities in the setting of long- term virological suppression Antonella Castagna San Raffaele Scientific Institute, Milan.

Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages.

INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.

Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.

Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.

Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,

Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):

NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.

Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati,

Harry Lampiris, MD, Moderator Chief, ID Section, Medical Service, SFVAMC Professor of Clinical Medicine, UCSF.

PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa

Maternal Toxicity Management

Novel Antiretroviral Studies and Strategies

Switch to PI/r monotherapy

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

State Office of AIDS Update

HIV Tutoring By Alaina Darby.

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

Maternal Toxicity Management

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Maternal Toxicity Management

New/Optimal ARV Treatments Why ? & How

Switch from TDF to TAF GS-US Study GS-US Study

What’s New in the Perinatal Guidelines

Adult Guidelines Pretoria, Saturday 17th February 2018

Managing Women Living With HIV Infection

New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) HIV positive.

The Brazilian Experience

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

The Possibilities of PrEP: Introduction

Advances in HIV Care.

Treating HIV Infection:

Botswana Moving Forward with DTG

Translating Emerging HIV Data Into Clinical Practice

Is it Time for a Paradigm Change in HIV Management?

HIV : New Agents, New Strategies

Next Generation Capsid Inhibitor: GS–CA1

Adele Schwartz Benzaken

Why Dolutegravir? Daniel R. Kuritzkes, M.D.

Drug-resistant human immunodefiency virus

Update From Seattle 2017.

A glimpse to the future: The ARV pipeline up to how do we ensure it is affordable and acceptable? Helen McDowell Head of Government Affairs & Global.

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

HIV Update 2018: A Front Row Seat

ART Options and Treatment Decisions for Women of Reproductive Potential

Comparison of INSTI vs EFV

Medical Management of HIV Among Transgender Adults

TRANSITION TO TLD – ZIMBABWE REPORT

Investigational Approaches to Antiretroviral Therapy

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

Investigational Approaches to Antiretroviral Therapy

Dolutegravir in PEPFAR

Dual vs. Triple ART: What to start?

Characterizing Virological Suppression in Today's Treatment Paradigm

Updates From the International AIDS Conference (IAS 2019)

Undetectable = Untransmittable

Managing Syphilis in HIV Co-infected Patients: A Case-Based Approach

Presentation transcript:

Updates From CROI 2019: Treatment of HIV and Its Complications

Updates From CROI 2019: Treatment of HIV and Its Complications

CME Information

Nursing and Pharmacy Credits

Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

Grant Support for this Webinar

Navigating the Webinar

Poll 1

Poll 2

Poll 3

Updates From CROI 2019: Treatment of HIV and Its Complications

Financial Relationships With Commercial Entities

Learning Objectives

Pretest Question

Update from 2019 CROI

Possible cure of HIV infection

Possible cure of HIV-1 infection

Possible cure of HIV-1 infection

Possible cure of HIV-1 infection

HIV-1 Capsid inhibitor

HIV-1 Capsid inhibitor

HIV-1 Maturation inhibitor

HIV-1 Maturation inhibitor

RCT of Point of care viral load testing: STREAM study

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

Long acting injectable cabotegravir + rilpivirine

PRO140 (CCR5 mAb) alone for maintenance therapy

Dolutegravir/lamivudine: target not detected

Archived NRTI resistance and response to InSTI +2 NRTI

TAF vs. TDF in women: Virologic responses

TAF vs. TDF in women: Bone outcomes

TAF vs. TDF in women: Renal outcomes

NICHD P1081: RAL vs. EFV for pregnant WLWH

NICHD P1081: RAL vs. EFV for pregnant WLWH

DolPHIN: DTG vs. EFV for pregnant WLWH

DolPHIN: DTG vs. EFV for pregnant WLWH

DolPHIN: DTG vs. EFV for pregnant WLWH

INSTI use during pregnancy

Levonorgestrol (LNG) implants and efavirenz

Quadrivalent HPV vaccine to improve response to LEEP treatment

Doxycycline vs. extended azithromycin for LGV proctitis

VACS: HIV and the risk of sudden cardiac death

VACS: HIV and the risk of sudden cardiac death

Opioid overdose deaths in PLWH

Opioid overdose deaths in PLWH

Integrase inhibitors and weight gain

Integrase inhibitors and weight gain

Weight gain after switch to integrase inhibitor

Weight Gain After Switch to INSTI-Based ART by Agent, Pre-Switch ART Class, and NRTI Backbone at Switch

Predictors of weight gain in an observational cohort

Predictors of weight gain in an observational cohort

HPTN 077: cabotegravir PrEP and weight gain

HPTN 077: cabotegravir and weight gain

Summary

Posttest Question

Question-and-Answer

Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

Final Poll

Sexual Health, HIV Prevention, and Primary Care in 2019

Thank You